Selexis, Tallac to advance novel immunotherapies

By The Science Advisory Board staff writers

March 23, 2021 -- Selexis and Tallac Therapeutics have signed both a commercial license agreement and service agreement to advance Tallac's toll-like receptor agonist antibody conjugate (TRAAC) platform.

Under the agreements, Tallac will use Selexis' proprietary Suretechnology platform to develop research cell banks to bring its immunotherapy candidates for the treatment of solid tumors to the clinic.

Tallac is developing therapeutics with the potential to activate innate and adaptive antitumor immunity. Its TRAAC platform, which delivers a potent toll-like receptor 9 agonist (T-CpG) for targeted immune activation via systemic administration, has been used to develop a pipeline of next-generation immunotherapies across multiple tumor indications.

Selexis' modular Suretechnology platform facilitates the rapid, stable, and cost-effective production of recombinant proteins and vaccines.

ALX, Tallac collaborate on novel immunotherapies
ALX Oncology Holdings and Tallac Therapeutics are joining forces to develop, manufacture, and commercialize a novel class of cancer immunotherapeutics.
Bosc named president of Women in Bio
Jessica Bosc, director of business development and licensing at Selexis, has been named president of Women in Bio, following a one-year term as president-elect.

Copyright © 2021

Last Updated ls 3/23/2021 9:51:41 AM